Literature DB >> 28663189

Erratum. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 2016;65:3418-3428.

Camillo Ricordi, Julia S Goldstein, A N Balamurugan, Gregory L Szot, Tatsuya Kin, Chengyang Liu, Christine W Czarniecki, Barbara Barbaro, Nancy D Bridges, Jose Cano, William R Clarke, Thomas L Eggerman, Lawrence G Hunsicker, Dixon B Kaufman, Aisha Khan, David-Erick Lafontant, Elina Linetsky, Xunrong Luo, James F Markmann, Ali Naji, Olle Korsgren, Jose Oberholzer, Nicole A Turgeon, Daniel Brandhorst, Andrew S Friberg, Ji Lei, Ling-Jia Wang, Joshua J Wilhelm, Jamie Willits, Xiaomin Zhang, Bernhard J Hering, Andrew M Posselt, Peter G Stock, A M James Shapiro.   

Abstract

Entities:  

Year:  2017        PMID: 28663189      PMCID: PMC5566298          DOI: 10.2337/db17-er09a

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


× No keyword cloud information.
In the article listed above, Xiaojuan Chen, now of the Columbia Center for Translational Immunology, Columbia University, New York, NY, was erroneously omitted from the author list. Dr. Chen contributed to the Clinical Islet Transplantation (CIT) trial as director of the islet processing team at the Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine (Chicago, IL). Her direct involvement resulted in 15 patients receiving islet transplants at Northwestern University. She specifically supervised the technical staff of the islet team on every aspect of islet processing procedure, which led to the successful utilization of the SERVA enzymes for pancreas digestion and islet recovery. She also participated in the development of the modified glucose-stimulated insulin release assay used by the CIT trial for islet quality evaluation in vitro. The authors apologize for this unfortunate omission. The online version has been updated to correct this omission.
  4 in total

1.  Mitigating hypoxic stress on pancreatic islets via in situ oxygen generating biomaterial.

Authors:  Maria M Coronel; Ryan Geusz; Cherie L Stabler
Journal:  Biomaterials       Date:  2017-03-18       Impact factor: 12.479

2.  An elastin-based vasculogenic scaffold promotes marginal islet mass engraftment and function at an extrahepatic site.

Authors:  Silvia Minardi; Michelle Guo; Xiaomin Zhang; Xunrong Luo
Journal:  J Immunol Regen Med       Date:  2018-12-10

3.  Human Hemangioblast-Derived Mesenchymal Stem Cells Promote Islet Engraftment in a Minimal Islet Mass Transplantation Model in Mice.

Authors:  Suzanne Bertera; Michael F Knoll; Carmela Knoll; Hidetaka Hara; Erin A Kimbrel; Nickolas A Kouris; Robert Lanza; Brett E Philips; Yesica Garciafigueroa; Nick Giannoukakis; David K C Cooper; Massimo Trucco; Rita Bottino
Journal:  Front Med (Lausanne)       Date:  2021-04-15

Review 4.  Pancreas-on-a-Chip Technology for Transplantation Applications.

Authors:  Shadab Abadpour; Aleksandra Aizenshtadt; Petter Angell Olsen; Kayoko Shoji; Steven Ray Wilson; Stefan Krauss; Hanne Scholz
Journal:  Curr Diab Rep       Date:  2020-11-18       Impact factor: 4.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.